Phagocytosis Modulation Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Category | Immunomodulation |
| Target | Microglial phagocytosis |
| Mechanism | Enhance or modulate clearance |
| Diseases | AD, PD, ALS, MS |
Phagocytosis modulation represents an emerging therapeutic strategy targeting the immune system's ability to clear pathological proteins and cellular debris in neurodegenerative diseases. Microglia, the brain's resident immune cells, are critical for maintaining neural homeostasis through phagocytic clearance of Aβ plaques, dead neurons, and protein aggregates.
Dysfunctional phagocytosis contributes to disease progression through:
TREM2 Agonism
CD33 Modulation
Scavenger Receptor Targeting
Pro-resolving Mediators
TREM2 Signaling
Aβ Plaque Clearance
TREM2 Targeting
CD33 Inhibition
α-Synuclein Clearance
Neuroinflammation Control
TREM2 in ALS
DAM Activation
Myelin Clearance
DAM in MS
| Target | Function | Therapy Approach | Status |
|---|---|---|---|
| TREM2 | Phagocytosis receptor | Agonist antibodies | Phase 1/2 |
| CD33 | Inhibitory receptor | Antagonist antibodies | Preclinical |
| CD36 | Scavenger receptor | Small molecules | Preclinical |
| CR3 | Complement receptor | Agonist modulation | Preclinical |
| SR-A | Scavenger receptor | Gene therapy | Preclinical |
| Trial | Drug | Target | Phase | Status |
|---|---|---|---|---|
| NCT04718935 | AL002 | TREM2 | Phase 2 | Recruiting |
| NCT04639079 | AL003 | TREM2 | Phase 1 | Completed |
| NCT03822208 | anti-CD33 | CD33 | Phase 1 | Completed |
| NCT03828747 | Lecanemab | Aβ plaques | Phase 3 | Completed |
| Biomarker | Significance |
|---|---|
| sTREM2 | TREM2 signaling activity |
| YKL-40 | Microglial activation |
| MCP-1 | Monocyte recruitment |
| IL-1β | Inflammatory status |
| TREM2 expression | Phagocytic capacity |
The study of Phagocytosis Modulation Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Wolf, M.S. et al. (2022). Microglia and Alzheimer's disease. Nature Reviews Neuroscience, 23(9), 539-549.
[2] Colonna, M. & Wang, Y. (2016). TREM2 variants: new keys to decipher Alzheimer disease. Nature Reviews Neurology, 12(11), 625-630.
[3] Huang, Y. et al. (2021). Microglial phagocytosis in neurodegenerative disease. Neuron, 109(7), 1104-1118.
[4] Ulrich, J.D. et al. (2017). TREM2 and neurodegeneration. Trends in Pharmacological Sciences, 38(10), 979-988.
[5] Gratuze, M. et al. (2020). TREM2 deficiency in Alzheimer's disease. Brain, 143(8), 2385-2399.
[6] Shi, Y. & Holtzman, D.M. (2018). Autoimmunity and Alzheimer's disease. Nature Reviews Immunology, 18(10), 623-638.
[7] Deczkowska, A. et al. (2020). TREM2 as a therapeutic target. Science, 368(6498), eaav0789.
[8] Hansen, D.V. et al. (2018). Microglia in development and disease. Neuron, 99(4), 691-704.